GC
KBIO

Guggenheim Capital’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

Guggenheim Capital’s Portfolio KBIO Stock Details KBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,523
Closed -$33K – 3438
2014
Q1 		$33K Buy
+1,523
New +$44.1K ﹤0.01% 3184

Other funds holding KBIO

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Guggenheim Capital's KBIO Position: Q2 2014 in Review

Guggenheim Capital sold out of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) in Q2 2014, closing a stake of 1,523 shares — an estimated $33K sold.

Guggenheim Capital first reported a position in KBIO in Q1 2014 and held it in 1 quarter. The position peaked at $33K in Q1 2014. 43 funds tracked by Wall St. Rank hold KBIO as of Q2 2014.

  • Guggenheim Capital reported no remaining KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position as of Q2 2014 after selling out during the quarter.
  • Guggenheim Capital sold 1,523 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q2 2014, an estimated $33K.
  • Guggenheim Capital first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q1 2014 and held it in 1 quarter.
  • Guggenheim Capital's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $33K in Q1 2014.
  • 43 funds tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q2 2014.

Based on Guggenheim Capital's 13F filing for Q2 2014, filed 14 Aug 2014.